CA3119786A1 - Compositions de cannabinoides - Google Patents

Compositions de cannabinoides Download PDF

Info

Publication number
CA3119786A1
CA3119786A1 CA3119786A CA3119786A CA3119786A1 CA 3119786 A1 CA3119786 A1 CA 3119786A1 CA 3119786 A CA3119786 A CA 3119786A CA 3119786 A CA3119786 A CA 3119786A CA 3119786 A1 CA3119786 A1 CA 3119786A1
Authority
CA
Canada
Prior art keywords
composition
formulation
phospholipids
approximately
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3119786A
Other languages
English (en)
Inventor
Caleb Joshua Eades
Orion LEKOS
Giri CHEEKATI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tilray Brands Inc
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CA3119786A1 publication Critical patent/CA3119786A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions pour l'administration de cannabinoïdes, y compris des formes comestibles de cannabinoïdes. Les phospholipides et les cires peuvent être utilisés pour contrôler le moment de l'apparition des effets de médicament de cannabis.
CA3119786A 2017-11-17 2018-11-19 Compositions de cannabinoides Pending CA3119786A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762558059P 2017-11-17 2017-11-17
US62/558,059 2017-11-17
US201862654815P 2018-04-09 2018-04-09
US62/654,815 2018-09-04
PCT/US2018/061833 WO2019100007A1 (fr) 2017-11-17 2018-11-19 Compositions de cannabinoïdes

Publications (1)

Publication Number Publication Date
CA3119786A1 true CA3119786A1 (fr) 2019-05-23

Family

ID=66539693

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3119786A Pending CA3119786A1 (fr) 2017-11-17 2018-11-19 Compositions de cannabinoides

Country Status (2)

Country Link
CA (1) CA3119786A1 (fr)
WO (1) WO2019100007A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3863614A1 (fr) * 2018-10-10 2021-08-18 Tilray, Inc. Procédés et formulations pour traiter la nausée et les vomissements induits par la chimiothérapie
WO2020176547A1 (fr) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthèse de cannabinoïdes et de précurseurs cannabinoïdes
US20210038558A1 (en) * 2019-08-07 2021-02-11 Orochem Technologies Inc. Water-soluble cannabinoids

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160184258A1 (en) * 2005-11-07 2016-06-30 Murty Pharmaceuticals, Inc. Oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2979184C (fr) * 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Compositions et methodes a base de nanoparticules lipidiques en tant que support de cannabinoides sous des formes posologiques dosees avec precision
CA2952335A1 (fr) * 2015-12-19 2017-06-19 Delta 9 Gardening B.V. Formulations d'administration therapeutique et systemes renfermant des cannabinoides et des terpenes

Also Published As

Publication number Publication date
WO2019100007A1 (fr) 2019-05-23

Similar Documents

Publication Publication Date Title
US20210186870A1 (en) Improved cannabinoid bioavailability
CA2438097C (fr) Preparations pharmaceutiques cannabinoides
US10004684B2 (en) Pharmaceutical formulations
KR20190029660A (ko) 고강도 경구 칸나비노이드 투여 형태
AU2018100110A4 (en) Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto
US20200093787A1 (en) Cannabinoid Compositions
US20030021752A1 (en) Pharmaceutical formulations
US20190054176A1 (en) Compositions of therapeutic substances, methods and uses thereof
AU2002231970A1 (en) Mucoadhesive pharmaceutical formulations
CA3119786A1 (fr) Compositions de cannabinoides
US20200330425A1 (en) Lozenge for improved delivery of cannabinoids
US20180042842A1 (en) Pharmaceutical formulations
KR20220118493A (ko) 칸나비노이드 경구 제제
US10188628B1 (en) Release composition for derivatives of Cannabaceae
GB2381194A (en) Pharmaceutical formulations
CA2533400C (fr) Preparations pharmaceutiques cannabinoides
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
US11826320B2 (en) Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm
EP4176869A1 (fr) Préparation et utilisation de nano-formulation de cannabis
WO2022027053A1 (fr) Préparations de micelles d'huile de chanvre à spectre complet pour le traitement du diabète de type ii, la réduction de l'inflammation pendant le covid-19 et l'amélioration de la qualité du sommeil
PL216740B1 (pl) Preparat w postaci płynnego sprayu